This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Winters, M. A.
Right arrow Articles by Holodniy, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Winters, M. A.
Right arrow Articles by Holodniy, M.

 Previous Article  |  Next Article 

Journal of Virology, April 2006, p. 4196-4199, Vol. 80, No. 8
0022-538X/06/$08.00+0     doi:10.1128/JVI.80.8.4196-4199.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Hepatitis C Virus Protease Gene Diversity in Patients Coinfected with Human Immunodeficiency Virus

Mark A. Winters,1 Seth L. Welles,2 and Mark Holodniy1,3*

Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, California,1 Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts,2 AIDS Research Center, VA Palo Alto Health Care System, Palo Alto, California3

Received 7 October 2005/ Accepted 1 February 2006

The clonal variability of the hepatitis C virus (HCV) protease gene in 24 individuals with HCV genotypes 1a, 1b, 2b, and 3a who were coinfected with the human immunodeficiency virus was evaluated. Within-genotype variability at the nucleotide and amino acid levels ranged from 6.5 to 8.6% and 2.2 to 3.8%, respectively. After adjustments were made for correlation of intrapatient clonal variation, mixed-model analysis indicated that nucleotide and amino acid variability among patients with different genotypes did not differ significantly. However, within individual patients, clonal variability differed by up to 5.3% and 5.8% at the nucleotide and amino acid levels, respectively, and genotype 1a had significantly greater nucleotide variability than other genotypes (P = 0.01). Significant variability exists within HCV protease gene variants at the patient level and could affect the effectiveness of HCV protease inhibitors.

* Corresponding author. Mailing address: AIDS Research Center, VA Palo Alto Health Care System, 3801 Miranda Ave. (132), Palo Alto, CA 94304. Phone: (650) 852-3408. Fax: (650) 858-3978. E-mail: holodniy{at}stanford.edu.

Journal of Virology, April 2006, p. 4196-4199, Vol. 80, No. 8
0022-538X/06/$08.00+0     doi:10.1128/JVI.80.8.4196-4199.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Pauwels, F., Mostmans, W., Quirynen, L. M. M., van der Helm, L., Boutton, C. W., Rueff, A.-S., Cleiren, E., Raboisson, P., Surleraux, D., Nyanguile, O., Simmen, K. A. (2007). Binding-Site Identification and Genotypic Profiling of Hepatitis C Virus Polymerase Inhibitors. J. Virol. 81: 6909-6919 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»